vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是READING INTERNATIONAL INC的1.5倍（$75.5M vs $50.3M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -14.2%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $4.1M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 5.6%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
PBYI vs RDI — 直观对比
营收规模更大
PBYI
是对方的1.5倍
$50.3M
营收增速更快
PBYI
高出41.9%
-14.2%
自由现金流更多
PBYI
多$10.3M
$4.1M
两年增速更快
PBYI
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $50.3M |
| 净利润 | — | $-2.6M |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | -1.9% |
| 净利率 | — | -5.1% |
| 营收同比 | 27.7% | -14.2% |
| 净利润同比 | — | -14.5% |
| 每股收益（稀释后） | $0.26 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIRDI
| Q4 25 | $75.5M | $50.3M | ||
| Q3 25 | $54.5M | $52.2M | ||
| Q2 25 | $52.4M | $60.4M | ||
| Q1 25 | $46.0M | $40.2M | ||
| Q4 24 | $59.1M | $58.6M | ||
| Q3 24 | $80.5M | $60.1M | ||
| Q2 24 | $47.1M | $46.8M | ||
| Q1 24 | $43.8M | $45.1M |
净利润PBYIRDI
| Q4 25 | — | $-2.6M | ||
| Q3 25 | $8.8M | $-4.2M | ||
| Q2 25 | $5.9M | $-2.7M | ||
| Q1 25 | $3.0M | $-4.8M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $20.3M | $-7.0M | ||
| Q2 24 | $-4.5M | $-12.8M | ||
| Q1 24 | $-4.8M | $-13.2M |
毛利率PBYIRDI
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYIRDI
| Q4 25 | 22.7% | -1.9% | ||
| Q3 25 | 17.6% | -0.6% | ||
| Q2 25 | 12.7% | 4.8% | ||
| Q1 25 | 8.7% | -17.2% | ||
| Q4 24 | 22.6% | 2.6% | ||
| Q3 24 | 27.4% | -0.6% | ||
| Q2 24 | -4.6% | -16.4% | ||
| Q1 24 | -5.3% | -16.7% |
净利率PBYIRDI
| Q4 25 | — | -5.1% | ||
| Q3 25 | 16.2% | -8.0% | ||
| Q2 25 | 11.2% | -4.4% | ||
| Q1 25 | 6.5% | -11.8% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | 25.2% | -11.7% | ||
| Q2 24 | -9.6% | -27.4% | ||
| Q1 24 | -11.0% | -29.4% |
每股收益（稀释后）PBYIRDI
| Q4 25 | $0.26 | $-0.11 | ||
| Q3 25 | $0.17 | $-0.18 | ||
| Q2 25 | $0.12 | $-0.12 | ||
| Q1 25 | $0.06 | $-0.21 | ||
| Q4 24 | $0.40 | $-0.11 | ||
| Q3 24 | $0.41 | $-0.31 | ||
| Q2 24 | $-0.09 | $-0.57 | ||
| Q1 24 | $-0.10 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $10.5M |
| 总债务越低越好 | $22.7M | $185.1M |
| 股东权益账面价值 | $130.3M | $-18.2M |
| 总资产 | $216.3M | $434.9M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYIRDI
| Q4 25 | $97.5M | $10.5M | ||
| Q3 25 | $94.4M | $8.1M | ||
| Q2 25 | $96.0M | $9.1M | ||
| Q1 25 | $93.2M | $5.9M | ||
| Q4 24 | $101.0M | $12.4M | ||
| Q3 24 | $96.7M | $10.1M | ||
| Q2 24 | $96.8M | $9.3M | ||
| Q1 24 | $107.2M | $7.5M |
总债务PBYIRDI
| Q4 25 | $22.7M | $185.1M | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | $202.7M | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
股东权益PBYIRDI
| Q4 25 | $130.3M | $-18.2M | ||
| Q3 25 | $115.3M | $-12.1M | ||
| Q2 25 | $104.7M | $-7.7M | ||
| Q1 25 | $97.1M | $-8.1M | ||
| Q4 24 | $92.1M | $-4.4M | ||
| Q3 24 | $71.1M | $1.6M | ||
| Q2 24 | $48.5M | $6.5M | ||
| Q1 24 | $51.0M | $18.0M |
总资产PBYIRDI
| Q4 25 | $216.3M | $434.9M | ||
| Q3 25 | $202.9M | $435.2M | ||
| Q2 25 | $194.9M | $438.1M | ||
| Q1 25 | $196.2M | $441.0M | ||
| Q4 24 | $213.3M | $471.0M | ||
| Q3 24 | $220.7M | $495.7M | ||
| Q2 24 | $205.0M | $494.9M | ||
| Q1 24 | $214.1M | $494.9M |
负债/权益比PBYIRDI
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $4.1M |
| 自由现金流率自由现金流/营收 | 19.1% | 8.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $41.7M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流PBYIRDI
| Q4 25 | $14.4M | $4.3M | ||
| Q3 25 | $9.7M | $295.0K | ||
| Q2 25 | $14.1M | $1.6M | ||
| Q1 25 | $3.6M | $-7.7M | ||
| Q4 24 | $15.6M | $8.0M | ||
| Q3 24 | $11.0M | $1.3M | ||
| Q2 24 | $1.0M | $-10.4M | ||
| Q1 24 | $11.2M | $-2.8M |
自由现金流PBYIRDI
| Q4 25 | $14.4M | $4.1M | ||
| Q3 25 | $9.7M | $-246.0K | ||
| Q2 25 | $14.1M | $1.2M | ||
| Q1 25 | $3.6M | $-8.0M | ||
| Q4 24 | $15.6M | $7.0M | ||
| Q3 24 | $11.0M | $-1.1M | ||
| Q2 24 | $1.0M | $-10.6M | ||
| Q1 24 | — | $-4.7M |
自由现金流率PBYIRDI
| Q4 25 | 19.1% | 8.2% | ||
| Q3 25 | 17.7% | -0.5% | ||
| Q2 25 | 26.8% | 1.9% | ||
| Q1 25 | 7.7% | -19.8% | ||
| Q4 24 | 26.4% | 12.0% | ||
| Q3 24 | 13.7% | -1.8% | ||
| Q2 24 | 2.1% | -22.7% | ||
| Q1 24 | — | -10.4% |
资本支出强度PBYIRDI
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.1% | 0.6% | ||
| Q4 24 | 0.0% | 1.7% | ||
| Q3 24 | 0.0% | 4.0% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | 0.0% | 4.3% |
现金转化率PBYIRDI
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | — | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
